Metastatic breast and colon cancer regulated genes

Abstract

Gene sequences as shown in SEQ ID NOS: 1-85 have been found to be significantly associated with metastatic potential of cancer cells, especially breast and colon cancer cells. Methods are provided for determining the risk of metastasis of a tumor, which involve determining whether a tissue sample from a tumor expresses a polypeptide encoded by a gene as shown in SEQ ID NOS: 1-85, or a substantial portion thereof.

We claim:  
     
         1 . An isolated and purified human protein comprising an amino acid sequence which is at least 85% identical to an amino acid sequence encoded by a nucleotide sequence selected from the group consisting of SEQ ID NOS:1-63 or the complement thereof.  
     
     
         2 . The isolated and purified human protein of  claim 1  wherein the amino acid sequence is at least 95% identical.  
     
     
         3 . The isolated and purified human protein of  claim 1  wherein the amino acid sequence is encoded by a sequence selected from the group consisting of SEQ ID NOS:1-63 or the complement thereof.  
     
     
         4 . A fusion protein which comprises ;a first protein segment and a second protein segment fused to each other by means of a peptide bond, wherein the first protein segment consists of at least six contiguous amino acids selected from an amino acid sequence encoded by a nucleotide sequence selected from the group consisting of SEQ ID NOS 1-63 or the complement thereof.  
     
     
         5 . A preparation of antibodies which specifically bind to a human protein which comprises an amino acid sequence encoded by a nucleotide sequence selected from the group consisting of SEQ ID NOS: 1-63 or the complement thereof.  
     
     
         6 . A method for detecting metastatic tumor cells in a tissue sample, comprising the step of: 
 measuring in said tissue sample an expression product of a gene which comprises a coding sequence selected from the group consisting of SEQ ID NOS:1, 2, 4, 5, 9, 11, 13, 14, 18, 19, 20, 22, 24, 26, 29, 30, 33, 35, 36, 38-41, 45, 48, 52, 55, 57, 58, 60, 63-66, 69-74, 76, 80, 82, and 83, wherein a tissue sample which expresses the product is categorized as containing metastatic tumor cells.    
     
     
         7 . The method of  claim 6  wherein the expression product is protein.  
     
     
         8 . The method of  claim 7  wherein the protein is measured using an antibody which specifically binds to the protein.  
     
     
         9 . A method for detecting metastatic tumor cells in a tissue sample, comprising the step of: 
 measuring in a tissue sample an expression product of a gene which comprises a sequence selected from the group consisting of SEQ ID NOS:3, 7, 8, 10, 12, 15-17, 21, 23, 25, 28, 31, 34, 37, 42-44, 46, 47, 49-51, 53, 59, 61, 62, 67, 68, 75, 77-79, 81, 84, and 85, wherein a tissue sample which does not express he product is categorized as metastatic.    
     
     
         10 . The method of  claim 9  wherein the expression product is protein.  
     
     
         11 . The method of  claim 10  wherein the protein is measured using an antibody which specifically binds to the protein.  
     
     
         12 . A method for determining metastatic potential in a tissue sample, comprising the step of: 
 measuring in a tissue sample an expression product of a gene which comprises a sequence selected from the group consisting of SEQ ID NOS:1, 2, 4, 5, 9, 11, 13, 14, 18, 19, 20, 22, 24, 26, 29, 30, 33, 35, 36, 38-41, 45, 48, 52, 55, 57, 58, 60, 63-66, 69-74, 76, 80, 82, and 83, wherein a tissue sample which expresses the product is categorized as having metastatic potential.    
     
     
         13 . The method of  claim 12  wherein the expression product is protein.  
     
     
         14 . The method of  claim 13  wherein the protein is measured using an antibody which specifically binds to the protein.  
     
     
         15 . A method for determining metastatic potential in a tissue sample, comprising the step of: 
 measuring in a tissue sample an expression product of a gene which comprises a sequence selected from the group consisting of SEQ ID NOS:3, 7, 8, 10, 12, 15-17, 21, 23, 28, 31, 34, 37, 42-44, 46, 47, 49-51, 53, 59, 61, 62, 67, 68, 75, 77-79, 81, 84, and 85, wherein a tissue sample which does not express the product is categorized as having metastatic potential.    
     
     
         16 . The method of  claim 15  wherein the expression product is protein.  
     
     
         17 . The method of  claim 16  wherein the protein is measured using an antibody which specifically binds to the protein.  
     
     
         18 . A method of predicting the propensity for metastatic spread of a breast tumor preferentially to bone or lung, comprising the steps of: 
 measuring in a breast tumor sample an expression product of a gene which comprises a sequence selected from the group consisting of SEQ ID NO:1, 5, 11, 18, 20, 22, 24, 30, 33, 35, 36, 38, 45, 52, 58, 65, 66, 70, 74, 76, and 80,    wherein a breast tumor sample which expresses the product is categorized as having a propensity to metastasize to bone or lung.    
     
     
         19 . A method of predicting propensity for metastatic spread of a breast tumor preferentially to lung, comprising the steps of: 
 measuring in a breast tumor sample an expression product of a gene which comprises a sequence selected from the group consisting of SEQ ID NOS:2, 4, 9, 13, 14, 19, 26, 29, 39-41, 48, 55, 57, 60, 63, 64, 72, 73, 82, and 83,    wherein a breast tumor sample which expresses the product is characterized as having a propensity to metastasize to lung.    
     
     
         20 . A method of predicting propensity for metastatic spread of a colon tumor, comprising the steps of: 
 measuring in a colon tumor sample an expression product of a gene which comprises the nucleotide sequence shown in SEQ ID NO:56,    wherein a colon tumor sample which expresses the product is characterized as having a low propensity to metastasize.